Table 6 Comparison between the studied groups regarding the clinical outcome
Clinical outcome | Group A (4–16 h deferral) | Group B (7 days deferral) | Group C (immediate) | p value |
|---|---|---|---|---|
In-hospital outcome | Number = 50 | Number = 50 | Number = 50 | |
Over-all MACE | 9 (18%) | 8 (16%) | 10 (20%) | 0.873 |
Death | 2 (4%) | 1 (2%) | 1 (2%) | 0.773 |
Re-infarction | 3 (6%) | 3 (6%) | 6 (12%) | 0.443 |
Arrhythmias | 5 (10%) | 5 (10%) | 3 (6%) | 0.714 |
Cardiac decompensation | 1 (2%) | 2 (4%) | 2 (4%) | 0.813 |
Stroke or TIA | 1 (2%) | 1 (2%) | 1 (2%) | 1.000 |
Bleeding | 3 (6%) | 3 (6%) | 2 (4%) | 0.876 |
CIN | 4 (8%) | 5 (10%) | 4 (8%) | 0.919 |
6-month outcome | Number = 48 | Number = 49 | Number = 49 | |
|---|---|---|---|---|
Over-all MACE | 7 (14.6%) | 8 (16.3%) | 17 (34.7%) | 0.029 |
Death | 1 (2.1%) | 2 (4.1%) | 3 (6.1%) | 0.605 |
Non-fatal MI | 3 (6.3%) | 4 (8.2%) | 5 (10.2%) | 0.778 |
Arrhythmias | 3 (6.3%) | 3 (6.1%) | 6 (12.2%) | 0.453 |
Heart failure | 4 (8.3%) | 2 (4.1%) | 7 (14.3%) | 0.205 |
Non-fatal stroke | 1 (2.1%) | 1 (2%) | 2 (4.1%) | 0.779 |
LVEF at 6 months (%) | 55 (50–59) | 53 (44–58) | 49.5 (40–55) | 0.009 |
Change in LVEF (%) | 11 (7–16) | 8 (5–15) | 5 (1.5–10) | 0.001 |